ProPhase Labs, Inc.

ProPhase Labs, Inc. has undergone significant operational changes, with its ProPhase Diagnostics subsidiary filing for Chapter 11 bankruptcy on September 22, 2025, due to a sharp decline in COVID-19 testing demand and reimbursement. Concurrently, the company divested its Pharmaloz Contract Manufacturing (PMI) unit on January 16, 2025, which included a $2 million cash payment and the extinguishment of approximately $11 million in debt. The company continues to focus on its growth-oriented biotech, genomics, and consumer products segments, including the development of the BE-Smart Esophageal Pre-Cancer diagnostic test and the Linebacker (LB-1 and LB-2) cancer therapies, alongside its Nebula Genomics, DNA Complete, and TK Supplements offerings.